retatrutide phase 2 weight loss results hits 28% in 3 retatrutide weight loss phase 2

Training shifts the ratio of weight loss toward fat and away from lean mass

For athletes who genuinely need weight loss for health reasons, these medications can be effective when combined with appropriate exercise and nutrition strategies

Over 50 warning letters were issued to GLP-1 compounders in September 2025 alone

Semaglutide (a GLP-1R monoagonist) achieved mean weight reductions of approximately 1517% in the STEP clinical trial programme (STEP-1, NEJM 2021)

Abstract Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimers disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs used to treat T2DM have been gradually found to reduce the progression of AD in AD models

Effects of Vegetables Consumption Before Carbohydrates on Blood Glucose and GLP-1 Levels Among Diabetic Patients in Indonesia